Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

PLG-0206

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

PLG-0206 is an engineered cationic antimicrobial peptide designed to treat drug-resistant and biofilm-associated bacterial infections. It is notable for its broad-spectrum activity against over 1,200 multidrug-resistant (MDR) clinical isolates and its potent anti-biofilm effects, making it a promising candidate for conditions such as periprosthetic joint infections
Huang et al. 2021 Antibiotics (Basel) 11(1): 41
Huang et al. 2021a Open Forum Infect Dis 8(Suppl 1): S641
Huang et al. 2022 PLoS ONE 17(9): e0274815
Huang et al. 2022a Antimicrob Agents Chemother 66(1):e0144121

PLG-0206 acts by disrupting bacterial cell mem…

References (Sources)

1098. A Phase 1 Safety and Tolerability of Single Ascending Doses of a Novel Engineered Cationic Peptide, PLG0206, in Healthy Subjects.
Huang et al. 2021a Open Forum Infect Dis 8(Suppl 1): S641
Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug class
Huang et al. 2022 PLoS ONE 17(9): e0274815
Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of a First-in-Human Engineered Cationic Peptide, PLG0206, Intravenously Administered in Healthy Subjects
Huang et al. 2022a Antimicrob Agents Chemother 66(1): e0144121
Prospective Activity of PLG0206, an Engineered Antimicrobial Peptide, on Chronic Periprosthetic Joint Infection Total Knee Arthroplasty Components Ex Vivo: The Knee Explant Analysis (KnEA) Study
Huang et al. 2021 Microbiol Spectr 9(3): e0187921
The Engineered Antibiotic Peptide PLG0206 Eliminates Biofilms and Is a Potential Treatment for Periprosthetic Joint Infections
Huang et al. 2021 Antibiotics (Basel) 11(1): 41
Review

AI Chat

7/1/2026

Chat with our artificial intelligence: